Indium (111in) Dtpa Curium Netherlands B.V (Pentetic Acid, Indium (111in) Pentetate)

The drug consists of the gamma‑emitting radionuclide Indium‑111 chelated by DTPA (pentetic acid). After intrathecal injection, the complex stays within the CSF, distributing with the fluid. External gamma cameras detect the emitted radiation, producing images that reveal CSF pathways and any abnormal tracer accumulation.

The prescribed dose of Indium-111 pentetate is determined by the treating physician or nuclear medicine specialist based on the specific diagnostic protocol, patient characteristics, and imaging equipment. Dosing is individualized and not standardized in public literature.

Safety data for Indium-111 pentetate in pregnancy and lactation are limited. It is generally avoided unless the diagnostic benefit outweighs potential risks. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their healthcare provider.

To order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Indium-111 pentetate offers gamma‑emission imaging, which provides high‑resolution functional data without the need for positron emission tomography. Compared with iodine‑based contrast agents, it allows quantitative assessment of CSF dynamics and has a longer half‑life, enabling delayed imaging, but requires radiation safety precautions.

The product should be stored refrigerated at 2‑8 °C, protected from light, and never frozen or shaken. It must be kept in its original container until use, and handling should follow radiopharmacy guidelines to prevent contamination and ensure radiation safety.

Indium-111 pentetate is administered by a trained professional via intrathecal injection, typically through a lumbar puncture. The procedure is performed under sterile conditions, and the patient is monitored for any immediate adverse reactions following administration.

Serious risks include allergic reactions that can progress to anaphylaxis, radiation‑induced myelopathy, severe hypotension, spinal hemorrhage, and infection at the injection site. Prompt recognition and management of these events are essential, and patients should be observed after the procedure.

Individuals with known hypersensitivity to DTPA or any component of the formulation should avoid the product. Patients with uncontrolled bleeding disorders, active spinal infections, or those for whom radiation exposure poses an undue risk should also be excluded, pending clinical judgment.